Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jun 15, 2024 11:04am
37 Views
Post# 36090492

RE:RE:RE:Inflation Reduction Act (IRA) boosts biological drugs

RE:RE:RE:Inflation Reduction Act (IRA) boosts biological drugs For example, while the Trump administration was working to erode a rules based society, just this past Thursday the European Commission accused India-based pharma company Alchem International of taking part in a “long-lasting cartel” to fix the minimum price of a widely used pharmaceutical ingredient. This regulatory action emphasizes the need to protect the best interest of the common person despite the Trump's administration accelerated actions to try to weaken or destroy the fundamental rules based / regulatory environment that had been developed to protect the health and economic interests of the broader electorate.  

https://www.biospace.com/article/eu-says-india-s-alchem-is-part-of-international-drug-price-fixing-cartel-/
<< Previous
Bullboard Posts
Next >>